Apogee Therapeutics, Inc.

NasdaqGM APGE

Apogee Therapeutics, Inc. Market Capitalization on January 14, 2025: USD 2.24 B

Apogee Therapeutics, Inc. Market Capitalization is USD 2.24 B on January 14, 2025, a 35.10% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Apogee Therapeutics, Inc. 52-week high Market Capitalization is USD 3.55 B on March 13, 2024, which is 58.63% above the current Market Capitalization.
  • Apogee Therapeutics, Inc. 52-week low Market Capitalization is USD 1.61 B on January 17, 2024, which is -28.19% below the current Market Capitalization.
  • Apogee Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 2.59 B.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
NasdaqGM: APGE

Apogee Therapeutics, Inc.

CEO Dr. Michael Thomas Henderson M.D.
IPO Date July 14, 2023
Location United States
Headquarters 221 Crescent Street
Employees 91
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

StockViz Staff

January 15, 2025

Any question? Send us an email